The United States diabetes market reached a value of over US$ 45 Million in 2018. Diabetes, also referred to as diabetes mellitus, is a group of metabolic diseases in which a person suffers from high blood glucose. This can be either caused by the inappropriate response to insulin by the body, inadequate insulin production. If not monitored properly, diabetes can be fatal and cause serious health complications such as heart diseases, stroke, amputation, blindness and kidney diseases. According to the Centers for Disease Control and Prevention (CDC), more than 30 million adults have been diagnosed with diabetes or prediabetes in the United States. In 2018, the United States represented the third largest diabetes patient pool owing to the increasing geriatric population and rising obesity levels. Apart from this, physical inactivity and unhealthy lifestyle have further contributed to the escalating diabetic population.
The increasing diabetes prevalence has led the Government of US to launch diabetes prevention programs, raise awareness about its symptoms and encourage healthier lifestyle behavior amongst the citizens. In line with this, there has been a rise in diabetes diagnosis, monitoring and drug treatment rates. Moreover, the FDA has approved the production of Basaglar and Admelog, the biosimilar versions of insulin glargine and lispro. Several other diabetes drugs are also expected to gain approval in the coming years, which will further drive the growth of the market. Apart from this, rapid technological advancements have enabled the manufacturers to develop continuous glucose monitoring (CGM) device. It allows type-2 diabetes patients to check their blood periodically with the help of testing strips and easily monitor their blood sugar levels. Looking forward, IMARC Group expects the market value to exceed US$ 77 Million by 2024, at a projected CAGR of around 9% during 2019-2024.
Breakup by Segment:
- Insulin
- Oral Antidiabetics
At present, insulin exhibits a clear dominance over oral antidiabetics on account of the convenience and efficacy of insulin delivery devices. Amongst the various product types, long acting insulin represents the largest insulin class in the US, whereas DPP-IV inhibitors are the leading oral-antidiabetics class in the nation.
Competitive Landscape:
The report has examined the competitive landscape of the market and finds that it is highly fragmented in nature with the presence of numerous small and large manufacturers. Some of the key players operating in the market are:
- Sanofi US Services Inc.
- Novo Nordisk Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Zeneca Holdings Inc.
- Johnson & Johnson
What we have achieved in this report:
Comprehensive situation analysis of the US diabetes epidemiology and its dynamics:
Focus of the Analysis:
- Historical, current and future prevalence of diabetes in US
- Historical, current and future prevalence of type-1 and type-2 diabetes in US
- Historical, current and future prevalence of diabetes in the urban and rural regions in US
- Historical, current and future prevalence of diabetes among males and females in US
- Historical, current and future prevalence of diabetes among various age groups in US
- Historical, current and future diagnosis rates for diabetes in US
- Historical, current and future drug treatment rates for diabetes in US
Comprehensive situation analysis of the US Oral Antidiabetics market and its dynamics:
Focus of the Analysis:
- Performance of the Oral Antidiabetics market in US
- Performance of key classes
- Performance of key players
- Market outlook
Comprehensive situation analysis of the US Insulin market and its dynamics:
Focus of the Analysis:
- Performance of the Insulin market in US
- Performance of key classes
- Performance of key players
- Market outlook
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Diabetes Disease Overview
5.1 What is Diabetes?
5.2 Diabetes Diagnosis and Treatment
5.2.1 Diagnosis
5.2.2 Treatment
5.3 Diabetes Complications
6 US Diabetes Epidemiology
6.1 Diabetes Population and Prevalence Rates
6.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2)
6.3 Population and Prevalence Rates by Region
6.4 Population and Prevalence Rates by Gender
6.5 Population and Prevalence Rates by Age Group
7 US Diabetes Market
7.1 Market Overview
7.2 Market Performance
7.3 Market Forecast
7.4 SWOT Analysis
7.4.1 Overview
7.4.2 Strengths
7.4.3 Weaknesses
7.4.4 Opportunities
7.4.5 Threats
7.5 Value Chain Analysis
7.6 Porter’s Five Forces Analysis
7.6.1 Overview
7.6.2 Bargaining Power of Buyers
7.6.3 Bargaining Power of Suppliers
7.6.4 Degree of Competition
7.6.5 Threat of New Entrants
7.6.6 Threat of Substitutes
7.7 Market Breakup by Segment
7.7.1 US Oral Antidiabetics Market
7.7.1.1 Historical Market Trends
7.7.1.2 Market Breakup by Class
7.7.1.3 Market Shares of Key Players
7.7.1.4 Market Forecast
7.7.2 US Insulin Market
7.7.2.1 Historical Market Trends
7.7.2.2 Market Breakup by Class
7.7.2.3 Market Shares of Key Players
7.7.2.4 Market Forecast
8 Competitive Landscape
8.1 Competitive Structure
8.2 Key Players
8.3 Profiles of Key Players
List of Figures
Figure 1: The Impact of Diabetes in the Human Body
Figure 2: Diabetes Complications
Figure 3: Global: Breakup of Diabetes Patients by Region, (in %) 2018 & 2024
Figure 4: US: Overweight & Obese Population (in Million), 2011, 2018 & 2024
Figure 5: Body Mass Index and Relative risk of Type-2 Diabetes
Figure 6: US: Breakup of Total Population by Age Groups (0-14, 15-64 & 65+, in %), 2018
Figure 7: US: Diabetes Prevalence by Age Groups (in %), 2018
Figure 8: US: Total Number of Diabetes Patients (in ‘000), 2011-2018
Figure 9: US: Total Number of Diabetes Patients Forecast (in ‘000), 2019-2024
Figure 10: US (Type1 & Type2): Total Number of Diabetes Patients (in 000), 2011-2018
Figure 11: US (Type1 & Type2): Total Number of Diabetes Patients (in 000), 2019-2024
Figure 12: US (Urban & Rural): Total Number of Diabetes Patients (in 000), 2011 -2018
Figure 13: US (Urban & Rural): Total Number of Diabetes Patients (in 000), 2019-2024
Figure 14: US (Male & Female): Total Number of Diabetes Patients (in 000), 2011-2018
Figure 15: US (Male & Female): Total Number of Diabetes Patients (in 000), 2019-2024
Figure 16: US: Total Number of Diabetes Patients by Age Group (20-39, 40-59 & 60-79, in ‘000), 2011-2018
Figure 17: US: Total Number of Diabetes Patients by Age Group (20-39, 40-59 & 60-79, in ‘000), 2019-2024
Figure 18: US: Diabetes Drug Industry Overview
Figure 19: US: Diabetes Drug Market: Sales Value (in Million US$), 2011-2018
Figure 20: US: Diabetes Drug Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 21: US: Diabetes Drug Market: SWOT Analysis
Figure 22: US: Diabetes Drug Market: Value Chain Analysis
Figure 23: US: Diabetes Drug Market: Porters Five Forces Analysis
Figure 24: US: Diabetes Drug Market: Breakup of Insulin and Oral Antidiabetics (in %), 2011-2018
Figure 25: US: Diabetes Drug Market Forecast: Breakup of Insulin and Oral Antidiabetics (in %), 2019-2024
Figure 26: US: Oral Antidiabetics Market: Sales Value (in Million US$), 2011-2018
Figure 27: US: Oral Antidiabetics Market: Sales Share of Key Classes (in %), 2011 & 2018
Figure 28: US: Oral Anti-diabetics Market: Sales Share of Key Players (in %)
Figure 29: US: Oral Antidiabetics Market: Sales Value (in Million US$), 2019-2024
Figure 30: US: Insulin Market, (in Million US$), 2011-2018
Figure 31: US: Breakup of Insulin Market by Class (in %), 2018
Figure 32: US: Insulin Market: Sales Share of Key Players (in %)
Figure 33: US: Insulin Market Forecast: Sales Value (in Million US$), 2019-2024
List of Tables
Table 1: Diagnosis of Diabetes
Table 2: Global: Diabetes Population Breakup by Country (in 000’s), 2018 & 2024
Table 3: US: Overweight & Obesity Statistics, 2011, 2018 & 2024
Table 4: US: Breakup of Total Population by Age Groups (0-14, 15-64 & 65+, in Million)
Table 5: US: Total Prevalence & Number of Diabetes Patients (in ‘000), 2011, 2018 & 2024
Table 6: US (Type1 & Type2): Total Prevalence & Number of Diabetes Patients (in ‘000), 2011, 2018 & 2024
Table 7: US (Urban & Rural): Total Prevalence & Number of Diabetes Patients (in ‘000), 2011, 2018 & 2024
Table 8: US (Male & Female): Total Prevalence & Number of Diabetes Patients (in ‘000), 2011, 2018 & 2024
Table 9: US: Total Prevalence & Number of Diabetes Patients by Age Group (20-39, 40-59 & 60-79, in ‘000), 2011, 2018 & 2024
Table 10: US: Diabetes Drug Market: Competitive Structure
Table 11: US: Diabetes Drug Market: Key Players